Your new experience awaits. Try the new design now and help us make it even better

BRIEF RESEARCH REPORT article

Front. Immunol.

Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1640532

This article is part of the Research TopicHunting for Inflammation Mediators: Identifying Novel Biomarkers for Autoimmune and Autoinflammatory DiseasesView all 12 articles

Cell-free DNA integrity and Complement C4d as Novel Liquid Biopsy Biomarkers for Paraneoplastic and Non-Paraneoplastic Autoimmune Encephalitis

Provisionally accepted
Aigli  G VakrakouAigli G Vakrakou1*Maria Evgenia  BriniaMaria Evgenia Brinia1Anastasia  CheirakiAnastasia Cheiraki1Anastasia  AlexakiAnastasia Alexaki1Anna  PapadopoulouAnna Papadopoulou1Giannis  VatsellasGiannis Vatsellas2Vasileia  Kokala DimitropoulouVasileia Kokala Dimitropoulou3Anastasia  DerventziAnastasia Derventzi4Vassilios  C ConstantinidesVassilios C Constantinides1Panos  StathopoulosPanos Stathopoulos1FOTINI  BOUFIDOUFOTINI BOUFIDOU1Leonidas  StefanisLeonidas Stefanis1Christine  StadelmannChristine Stadelmann5Stefan  NesslerStefan Nessler5Elisabeth  N KapakiElisabeth N Kapaki1Constantinos  KilidireasConstantinos Kilidireas1
  • 1First Department of Neurology, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece
  • 2Idryma Iatrobiologikon Ereunon tes Akademias Athenon, Athens, Greece
  • 3Aretaieion Panepistemiako Nosokomeio, Athens, Greece
  • 4Geniko Nosokomeio Athenon Ippokrateio, Athens, Greece
  • 5Georg-August-Universitat Gottingen, Göttingen, Germany

The final, formatted version of the article will be published soon.

Neuronal injury in Autoimmune encephalitis (AE) may involve antibodies or T cells, with or without complement activation. Cell-free DNA (cf-DNA), released during cell death, and the complement split product C4d may reflect underlying tissue damage and immune activation. This study examines cf-DNA and C4d levels in CSF and plasma of AE patients, focusing on differences between paraneoplastic and non-paraneoplastic subtypes. Thirty patients with AE (including paraneoplastic and non-paraneoplastic cases) and 18 healthy and disease controls were included. Total cf-DNA and cf-DNA integrity (cfDI), defined as the ALU-247/ALU-115 ratio, were measured in CSF and plasma using quantitative polymerase chain reaction (qPCR). Interleukins IL-6 and IL-17A, and complement split product C4d, were measured by ELISA. Clinical and radiological parameters were recorded. CSF cf-DNA levels were significantly elevated in AE patients compared to controls (p<0.01). Patients with paraneoplastic AE showed higher cfDI values (p<0.05), indicating a predominance of necrotic cell-death. CSF C4d levels were markedly increased in AE patients, particularly those with tumors (p<0.001). CSF C4d showed the highest diagnostic accuracy for detecting underlying tumors at AE diagnosis (AUC=0.818). Elevated CSF ALU-115 levels (p=0.025) were significantly associated with MRI-confirmed encephalitic lesions, while increased cfDI correlated with electroencephalogram abnormalities indicative of epileptiform activity, underscoring their potential as biomarkers of disease severity. Elevated CSF levels of necrotic cf-DNA and complement split product C4d reflect heightened CNS tissue injury and inflammatory activity in AE, particularly in paraneoplastic cases. These biomarkers may serve as useful tools for early diagnosis, disease monitoring, and subtype differentiation in AE.

Keywords: cell-free DNA, C4d, Encephalitis, tumor, IL-17A, IL-6, Apoptosis, Necrosis

Received: 03 Jun 2025; Accepted: 26 Aug 2025.

Copyright: © 2025 Vakrakou, Brinia, Cheiraki, Alexaki, Papadopoulou, Vatsellas, Kokala Dimitropoulou, Derventzi, Constantinides, Stathopoulos, BOUFIDOU, Stefanis, Stadelmann, Nessler, Kapaki and Kilidireas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Aigli G Vakrakou, First Department of Neurology, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.